This is a Phase 3, randomized, double-blind, placebo-controlled, multinational, efficacy and safety study of subjects with IPF treated with inhaled treprostinil over a 52-week period.
The study will run for about 58 weeks and will entail at least 8 visits to the clinical trials unit. Patients will be required to complete the below;
September 2022 - November 2024
A new diagnostic and treatment approach for bladder cancer will undergo a clinical trial in Queensland.
2023 was an outstanding year for Mater Research with $13.7 million in grant funding received and 424 publications recorded.
When Monique Perry was diagnosed with aggressive triple-negative breast cancer she feared her family history was about to repeat itself.